✦ LIBER ✦

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment

✍ Scribed by Jian-Wu Yu; Li-Jie Sun; Yong-Hua Zhao; Peng Kang; Bing-Zhu Yan

Book ID: 118452096
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 247 KB
Volume: 15
Category: Article
ISSN: 1201-9712
DOI: 10.1016/j.ijid.2011.05.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early virologic response after peginterf

Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

✍ A. M. Di Bisceglie; R. H. Ghalib; F. M. Hamzeh; V. K. Rustgi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

PP-147 Impact of gender on virologic res

PP-147 Impact of gender on virologic responses rates in genotype 1 chronic hepatitis C patients with peginterferon alfa-2a and ribavirin treatment

✍ J.-W. Yu; L.-J. Sun 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Peginterferon alfa-2a and ribavirin for

Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

✍ C. D. Howell; L. S. Jeffers; W. Cassidy; K. R. Reddy; S. Hu; J. S. Lee 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Response to peginterferon-alpha 2b and r

Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1

✍ Tomoo Miyauchi, Tatsuo Kanda, Fumio Imazeki, Rintaro Mikata… 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 293 KB

Early virologic response and IL28B polym

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin

✍ Thomas-Matthias Scherzer; Harald Hofer; Albert Friedrich Staettermayer; Karoline 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 801 KB

Virologic response rates of weight-based

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

✍ Fred Poordad; Eric Lawitz; Mitchell L. Shiffman; Tarek Hassanein; Andrew J. Muir 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB 👁 1 views

Muir is a consultant for, is on the speakers' bureau of, and received grants from Merck. He received grants from Valeant. He is also a consultant for and received grants from Zynogenetics. Dr. Poordad is a consultant for and received grants from Valeant. Dr. Shiffman advises and received grants from